Form 4: Myriad Genetics SVP Margaret Ancona Reports Acquisition of 6,468 Shares of Common Stock

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports the acquisition of 6,468 shares of common stock on February 7, 2025, related to performance-based restricted stock units.

Summary

• On February 7, 2025, Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, acquired 6,468 shares of common stock.
• The acquisition was related to performance-based restricted stock units (PSUs) granted on March 22, 2022.
• The final award amount was determined by the Compensation and Human Capital Committee of the Company's Board of Directors based on the accomplishment of pre-determined performance metrics.
• Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 22, 2025.
• Following the transaction, Ancona beneficially owns 82,171 shares of Myriad Genetics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction related to executive compensation. The acquisition of shares by an executive is generally viewed as a positive sign, but it's a routine event.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the PSUs on March 22, 2025, will result in the issuance of common stock to Margaret Ancona.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies and their executives, providing transparency into insider transactions.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the executive's increased stake in the company.

Next Steps

• Vesting of the PSUs on March 22, 2025, resulting in the issuance of common stock.

Key Dates